original articlessupportive careA phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
supportive care
Under a Creative Commons license
open access
Key words
neurokinin-1 receptor antagonist
NEPA
netupitant
palonosetron
CINV
multiple chemotherapy cycles
Cited by (0)
Copyright © 2014 THE AUTHORS. Published by Elsevier Ltd.